Bio Product Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Immediate Supply Available in the United States | Instant News

ALBUMINEX 5% and ALBUMINEX 25% are albumin products derived from human plasma using a four-step process that produces >99% purity. BPL has a long history of manufacturing and providing plasma protein therapy, including more than 25 years of global experience with albumin. For additional information, including how to order ALBUMINEX 5% and ALBUMINEX 25%, please visit or call 1-844-4BPLUSA.

“BPL is happy to add ALBUMINEX to our product portfolio at United States of America, “said Bob Rossilli, Chief of Commercial Staff and President of US Business Operations for BPL. “The introduction of ALBUMINEX is our third product launch in the US in the last five years, and it reflects our company’s mission to provide a sustainable supply of high-quality plasma derivative products worldwide, supporting healthcare professionals and patients every day.”


ALBUMINEX 5% and ALBUMINEX 25% are indicated for:

  • Hypovolemia
  • Ascites
  • Hypoalbuminemia, including from burns
  • Acute nephrosis
  • Adult respiratory distress syndrome (ARDS)
  • Bypass pulmonary heart

ALBUMINEX 5% and ALBUMINEX 25% are contraindicated in patients with:

  • Hypersensitivity to human albumin or one of the excipients
  • Severe anemia or heart failure with normal or increased intravascular volume

Please see additional Important Safety Information about ALBUMINEX 5% and ALBUMINEX 25% below, and Complete Prescribing Information at

Important Safety Information
Suspicion of an allergic reaction or anaphylaxis requires an immediate cessation of infusion and the implementation of appropriate medical care.

Hypervolemia can occur if the dose and infusion rate do not adjust to the patient’s volume status. In the first clinical signs of cardiovascular overload (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately. Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution can represent special risks for patients.

The colloidal-osmotic effect of human albumin is 25% about five times that of blood plasma. Therefore, when concentrated albumin is given, care must be taken to ensure adequate hydration in the patient. Patients must be monitored carefully to prevent over circulation and hyperhydration.

Albumin is a derivative of human blood. Based on an effective donor screening and product manufacturing process, it carries a huge risk for transmission of viral diseases. The theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered very far. No cases of viral disease or CJD transmission have been identified for ALBUMINEX 5% or ALBUMINEX 25%.

The most common adverse reactions associated with infusion of human albumin solution are harshness, hypotension / decreased BP, tachycardia / increased heart rate, fever, feelings of cold (coldness), nausea, vomiting, dyspnea / bronchospasm, rash / pruritus. The reaction usually disappears when the infusion is slowed or stopped.

About the Bio Product Laboratory United States of America (BPL United States of America)

BPL United States of America, is headquartered in Durham, NC, focusing on providing access to BPL-derived plasma therapy to the US market. BPL United States of America is dedicated to providing transformative therapy to patients in the fields of Immunology, rare bleeding disorders, and critical care. In addition to the five special drugs that are currently available on the US market, BPL also invests in developing strong pipelines for prospective future products for patients with rare and orphaned diseases. Since receiving the first US FDA approval in 2009, BPL has proudly built a culture and a strong reputation as an industry leader with specialized pharmacies, healthcare professionals, and patient advocacy organizations. BPL United States of America is part of a global company, the Bio Products Laboratory, which offers a dynamic 60-year heritage in plasma research, technology and manufacturing. For more information about BPL at United States of America, please visit

About the Bio Product Laboratory (BPL)

Recognizing the power of plasma and with a legacy of more than 60 years in the industry, BPL supplies high-quality plasma derivatives to meet the needs of doctors, patients and customers throughout the world. Headquartered in great Britain and with plasma collection centers throughout United States of America, we are dedicated to producing drugs for the treatment of immune deficiency, bleeding disorders, and infectious diseases and critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continues to adapt to ensure that we continue to serve all stakeholders effectively. For more information, visit

BPL consists of two operating divisions – BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered at Austin, Texas and operate in United States of America, collecting plasma from donors, in about 51 centers across the US. BPL Plasma employs more than 2000 staff, to support the needs of donors and ensure the collection of high-quality plasma in all their centers. Plasma collection is regulated by the FDA and MHRA, and Plasma BPL follows industry guidelines. BPL Plasma operates a clean and safe plasma facility, with trained staff, dedicated to supporting donors through a process that leads to plasma donations. Plasma is sent to the Therapeutics BPL headquarters in Elstree, great Britain. Plasma is fractionated, refined, and filled through the efforts of more than 1000 of our employees involved in production, quality, R&D, commercial, customer service, and administrative activities. BPL plasma derivatives are commercially available in the UK, United States of America and 30 plus other countries throughout the world through our network of local distribution partners.

SOURCE Bio Product Laboratory United States of America Inc.


image source

to request modification Contact us at Here or [email protected]